Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
NCT07377565Phase 1Recruiting
- Sponsor
- Nielsen Fernandez-Becker
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HB-2121 in celiac disease, sponsored by Nielsen Fernandez-Becker. Primary endpoint: Frequency and severity of adverse events at 30 days. Started Apr 2026; status: recruiting.
02
Drugs
HB-2121
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT07377565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377565.